Acute Porphyria Drug Database

J07BC01 - Hepatitis B, Purified Antigen
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the hepatitis B, purified antigen vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Hepatitis B surface antigen
Therapeutic characteristics
The vaccine is indicated for the active immunization of adults, children and infants against hepatitis B. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmacokinetics
The hepatitis vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). HBVAXPRO. (Last edition: March 2014). #1875

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BC or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙